| 000 | 03473nam a22003615i 4500 | ||
|---|---|---|---|
| 001 | 75964 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230202101824.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 130509s2013 xxu s 000 0 eng d | ||
| 020 | _a9781461468288 | ||
| 024 | 7 |
_a10.1007/978-1-4614-6828-8 _2doi |
|
| 050 | 4 |
_aRC280.P7 _bP76 2013 EB |
|
| 082 | 0 | 4 | _a614.5999 |
| 245 | 0 | 0 |
_aProstate Cancer : _bBiochemistry, Molecular Biology and Genetics _cedited by Donald J. Tindall |
| 260 |
_aNew York _bSpringer International Publishing _c2013 |
||
| 300 | _a1 recurso en línea (XII, 522 p.) | ||
| 336 |
_aTexto (visual) _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 490 | 1 |
_aProtein Reviews _v16 |
|
| 505 | 0 | _aPreface -- Section 1: Cell Biology -- Stem Cells in the Normal and Malignant Prostate -- Role of Reactive Stroma in Prostate Cancer -- The Role of Cholesterol in Prostate Cancer -- Section 2: Genetics: PTEN in Prostate Cancer -- ETS fusion genes in prostate cancer -- Section 3: Cell Signaling -- Signaling Mechanisms of Vav3, a Guanine Nucleotide Exchange Factor and Androgen Receptor Coactivator, in Physiology and Prostate Cancer Progression -- Transforming Growth Factor-beta (TGF-b) in Prostate Cancer -- The p38 MAPK Pathway in Prostate Cancer -- NF-kappaB2/p52 in Prostate Cancer -- The functional role of DAB2IP, a homeostatic factor, in prostate cancer -- Tyrosine Kinases in Prostate Cancer -- Human prostatic acid phosphatase in prostate carcinogenesis -- Section 4: Hormonal -- Truncated Androgen Receptor Splice Variants in Prostate Cancer -- Biology and Clinical Relevance of Estrogen Receptors in Prostate Cancer -- Vitamin D and Prostate Cancer -- HDAC6 regulation of androgen signaling in prostate cancer -- Beyond the cell cycle: Implications of D-type cyclin deregulation in Pca -- Section 5: Cell Death -- Role of Par- in Prostate Cancer -- Autophagy and Prostate Cancer Therapeutics -- Index | |
| 520 | _aProstate cancer is the most frequently diagnosed non-cutaneous malignancy in men, and the second leading cause of male cancer-related mortality in the United States. The last decade has seen unprecedented progress in the detection, prognosis, treatment and prevention of prostate cancer. These advances have been driven largely by an increased understanding of the underlying biochemistry, molecular biology and genetics of the disease. New cell and animal models have been developed that recapitulate the natural progression of prostate cancer. New technologies have allowed scientists to view in detail the genomic, proteomic, metabolomics and other -omic universe of cancer cells and tissues. This has resulted in a greater understanding of the pathophysiology of the disease | ||
| 942 |
_2lcc _cLE |
||
| 988 | _aEBOOK, EBSPRINGERrevisado | ||
| 650 | 7 |
_aPróstata _xCáncer _0comprobar BNE19901355947 _2embne _9182337 |
|
| 700 | 1 |
_aTindall, Donald J. _eeditor literario _984722 _0Local |
|
| 830 | 0 |
_aProtein Reviews _v16 _9133183 _0Local |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-6828-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 907 |
_a.b12815822 _b10-10-17 _c01-10-14 |
||
| 998 |
_am _a_alco _a_vill _b30-03-17 _cm _dz _eu _feng _gxxu _h0 |
||
| 945 |
_aRC280.P7 P76 2013 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11545203 _z06-04-17 |
||
| 999 |
_c75964 _d75964 _x1 |
||